Analysts Expect Xeris Pharmaceuticals Inc (NASDAQ:XERS) Will Post Quarterly Sales of $1.10 Million

Analysts expect that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will post $1.10 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Xeris Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.30 million and the lowest estimate coming in at $890,000.00. Xeris Pharmaceuticals posted sales of $800,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 37.5%. The business is scheduled to report its next quarterly earnings report on Wednesday, March 4th.

According to Zacks, analysts expect that Xeris Pharmaceuticals will report full year sales of $1.83 million for the current year, with estimates ranging from $1.46 million to $2.20 million. For the next financial year, analysts forecast that the business will report sales of $22.69 million, with estimates ranging from $22.17 million to $23.20 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Xeris Pharmaceuticals.

Xeris Pharmaceuticals (NASDAQ:XERS) last posted its earnings results on Thursday, November 7th. The company reported ($1.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.01. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.20 million.

XERS has been the topic of a number of recent research reports. ValuEngine lowered Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, September 30th. Mizuho reiterated a “buy” rating and issued a $22.00 target price on shares of Xeris Pharmaceuticals in a research report on Thursday, November 21st. Royal Bank of Canada set a $18.00 target price on Xeris Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, Zacks Investment Research upgraded Xeris Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 16th.

In other Xeris Pharmaceuticals news, insider Paul R. Edick bought 17,935 shares of Xeris Pharmaceuticals stock in a transaction dated Monday, November 25th. The stock was acquired at an average cost of $8.55 per share, with a total value of $153,344.25. Following the purchase, the insider now directly owns 172,935 shares in the company, valued at approximately $1,478,594.25. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Steven Prestrelski sold 27,700 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $9.00, for a total value of $249,300.00. Corporate insiders own 7.43% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Invesco Ltd. purchased a new stake in shares of Xeris Pharmaceuticals during the second quarter worth approximately $11,440,000. FMR LLC increased its position in shares of Xeris Pharmaceuticals by 29.9% during the first quarter. FMR LLC now owns 2,963,018 shares of the company’s stock worth $29,749,000 after purchasing an additional 682,050 shares in the last quarter. BlackRock Inc. increased its position in shares of Xeris Pharmaceuticals by 19.5% during the second quarter. BlackRock Inc. now owns 2,138,781 shares of the company’s stock worth $24,468,000 after purchasing an additional 348,308 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Xeris Pharmaceuticals during the third quarter worth approximately $918,000. Finally, Vanguard Group Inc. increased its position in shares of Xeris Pharmaceuticals by 7.1% during the second quarter. Vanguard Group Inc. now owns 1,219,153 shares of the company’s stock worth $13,947,000 after purchasing an additional 81,209 shares in the last quarter. 66.37% of the stock is owned by institutional investors and hedge funds.

Shares of XERS stock traded up $0.14 during trading hours on Friday, reaching $8.94. 125,806 shares of the company’s stock were exchanged, compared to its average volume of 196,196. The stock’s fifty day moving average price is $8.34 and its two-hundred day moving average price is $10.21. The stock has a market cap of $241.07 million, a PE ratio of -1.79 and a beta of -0.39. Xeris Pharmaceuticals has a 1 year low of $6.85 and a 1 year high of $20.90. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 1.33.

About Xeris Pharmaceuticals

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Featured Article: What is a front-end load?

Get a free copy of the Zacks research report on Xeris Pharmaceuticals (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xeris Pharmaceuticals (NASDAQ:XERS)

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.